Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
Aihua Li, Xiaorong Su, Shanshan Hu, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110605-110605
Closed Access | Times Cited: 23

Showing 23 citing articles:

Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 29
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 27
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 19
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba‐Yamamoto, et al.
Endocrine Journal (2024) Vol. 71, Iss. 6, pp. 603-616
Open Access | Times Cited: 7
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 6
Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Tianzuo Wang, Yuying Cui, Lin Liao
Diabetes Therapy (2025)
Open Access
Amphibian host-defense peptides with potential for Type 2 diabetes therapy – an updated review
J. Michael Conlon, Bosede O. Owolabi, Peter R. Flatt, et al.
Peptides (2024) Vol. 175, pp. 171180-171180
Open Access | Times Cited: 3
Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system
Kaibin Niu, Maoxia Fan, Wulin Gao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Seeking satiety: From signals to solutions
Matthias H. Tschöp, Jeffrey M. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 723
Closed Access | Times Cited: 9
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention
Chuanhao Xiong, Jingzhu Wu, Yuhang Ma, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 865-880
Open Access | Times Cited: 2
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 2
Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
Stefania Chiappini, Rachel Vickers‐Smith, Duccio Papanti, et al.
(2023)
Open Access | Times Cited: 6
Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)
Óscar Moreno, Rebeca Reyes‐García, Inés Modrego Pardo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 4, pp. 1519-1523
Open Access | Times Cited: 6
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae)
J. Michael Conlon, Ananyaa Sridhar, Dawood Khan, et al.
Biochimie (2024) Vol. 223, pp. 23-30
Open Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis
Lin Zhang, Zixin Hua, Zhenwei Fang, et al.
The Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Federico Losada-Díaz, Santiago Lizarazo-Bocanegra, Juan J Perdomo-Lugo, et al.
Diabetes Therapy (2024)
Open Access | Times Cited: 1
A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design
Tal Davidy, Iscka Yore, Tali Cukierman‐Yaffe, et al.
Mechanisms of Ageing and Development (2023) Vol. 218, pp. 111898-111898
Closed Access | Times Cited: 2
Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice
Paola Pantanetti, Vanessa Ronconi, Marco Sguanci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4752-4752
Open Access
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration
Xinxin Yang, Ruiting Lin, C Feng, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1353-1353
Open Access
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
(2023)
Open Access | Times Cited: 1
Reporte de Caso Clínico: Uso de Agonistas de GLP-1 y enlentecimiento del vaciamiento Gástrico: ¿Estómago Vacío?
F. Aguayo, Javiera Vargas, Daniel Asencio, et al.
Resumenes (2023)
Open Access
Page 1

Scroll to top